©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Jun 26, 2015; 5(2): 101-107
Published online Jun 26, 2015. doi: 10.5662/wjm.v5.i2.101
Published online Jun 26, 2015. doi: 10.5662/wjm.v5.i2.101
Current Helicobacter pylori treatment in 2014
Fatih Ermis, Department of Gastroenterology, Duzce University Faculty of Medicine, 81620 Duzce, Turkey
Elif Senocak Tasci, Department of Internal Medicine, Duzce University Faculty of Medicine, 81620 Duzce, Turkey
Author contributions: Ermis F and Senocak Tasci E contributed equally to this work, generated the tables and figures and wrote the manuscript.
Conflict-of-interest: The authors declare that there are no conflicts of interest.
Correspondence to: Fatih Ermis, MD, Associate Professor, Department of Gastroenterology, Duzce University Faculty of Medicine, Beciyorukler Street, Konuralp, 81620 Duzce, Turkey. fatihermis2@hotmail.com
Telephone: +90-53-34689404
Received: March 5, 2015
Peer-review started: March 5, 2015
First decision: April 10, 2015
Revised: April 28, 2015
Accepted: May 16, 2015
Article in press: May 18, 2015
Published online: June 26, 2015
Processing time: 124 Days and 19.8 Hours
Peer-review started: March 5, 2015
First decision: April 10, 2015
Revised: April 28, 2015
Accepted: May 16, 2015
Article in press: May 18, 2015
Published online: June 26, 2015
Processing time: 124 Days and 19.8 Hours
Core Tip
Core tip: In this review, we focused on different treatment regimens used for Helicobacter pylori eradication. The worldwide increase in antibiotic resistance, especially clarithromycin, caused change in the preferred initial treatments. The efficiency of bismuth-quadruple therapy, sequential, concomitant and hybrid therapies are emphasized in relation to each other. In addition, adjuvant therapies to increase the efficiency are reviewed. In conclusion, the optimal approach for eradication was found to be the individualized therapy.